- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| ICECURE MEDICAL Aktie jetzt für 0€ handeln | |||||
| Mi | IceCure Medical: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance | 342 | PR Newswire | Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated... ► Artikel lesen | |
| 02.06. | IceCure Medical to boost share price with 1-for-30 reverse split to regain Nasdaq compliance | 1 | Seeking Alpha | ||
| 02.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.06. | IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance | 247 | PR Newswire | Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy
CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical... ► Artikel lesen | |
| 19.05. | IceCure Medical: IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked | 226 | PR Newswire | At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors =3 cm and... ► Artikel lesen | |
| 13.05. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | IceCure Medical: IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement | 275 | PR Newswire | No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares
CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM)... ► Artikel lesen | |
| 12.05. | IceCure Medical GAAP EPS of $0.06, revenue of $911M | 3 | Seeking Alpha | ||
| 12.05. | IceCure Medical Ltd Q1 Sales Increase | 1 | RTTNews | ||
| 12.05. | IceCure Medical: IceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America | 405 | PR Newswire | Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared... ► Artikel lesen | |
| 10.05. | Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag | 32 | Seeking Alpha | ||
| 06.05. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.04. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | IceCure Medical Ltd. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 26.03. | IceCure prices $4M direct offering, concurrent private placement | 2 | Seeking Alpha | ||
| 25.03. | IceCure Medical Reports Positive Trial Results For ProSense Cryoablation System | 2 | RTTNews | ||
| 24.03. | IceCure Medical: IceCure Appoints Meir Peleg as Chief Financial Officer | 218 | PR Newswire | Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel... ► Artikel lesen | |
| 24.03. | IceCure Medical Appoints Meir Peleg As CFO; Shares Rise In Pre-market | - | RTTNews | ||
| 24.03. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,487 | -2,89 % | HEALWELL AI informiert über Neuigkeiten aus dem Unternehmen: Annahme der Forschungsergebnisse aus provinzübergreifendem KI-Pilotprojekt beim AMIA-Symposium und Stärkung der Bilanz durch SpaceX-Beteiligung | - HEALWELL hat erfolgreich ein Pilotprojekt zur Bewertung seiner auf DARWEN basierenden KI-Lösungen SMART Summary und SMART Search in mehreren kanadischen Provinzen
abgeschlossen. Das... ► Artikel lesen | |
| INSULET | 122,00 | -3,82 % | Insulet has a new chief R&D officer | ||
| LIFEWARD | 7,060 | +3,82 % | Lifeward Ltd.: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform | Veteran physician- medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience- mobility technologies, and metabolic disease... ► Artikel lesen | |
| IMUNON | 1,620 | 0,00 % | Imunon, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| LANTHEUS | 91,60 | +1,44 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| INSPIRE MEDICAL SYSTEMS | 37,600 | +1,08 % | Inspire Medical data highlights cardiovascular outcomes with neuromod for sleep apnea | ||
| INSPIREMD | 0,645 | +6,61 % | InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR | ||
| GT BIOPHARMA | 0,533 | +3,77 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| INOGEN | 5,600 | 0,00 % | Inogen Inc - S-8, Securities to be offered to employees in employee benefit plans | ||
| MYOMO | 1,118 | +0,36 % | Myomo übertrifft Q1-Prognosen, Aktie gibt dennoch nach | ||
| INTELLIGENT BIO SOLUTIONS | 2,350 | +2,62 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| INCANNEX HEALTHCARE | 3,230 | -9,27 % | Incannex Healthcare: Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility | NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 0,565 | +4,61 % | Lexaria Bioscience Corp.: GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand | More People Than Ever Taking GLP-1 Drugs for Weight LossGrowing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp.... ► Artikel lesen | |
| GLUCOTRACK | 0,384 | +4,21 % | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen | |
| HEARTFLOW | 34,360 | +2,14 % | Heartflow, Inc. - 8-K, Current Report |
Das Unternehmen ICECURE MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 6,525 Euro und damit +20,83 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ICECURE MEDICAL LTD finden Sie auf Wallstreet Online.